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D ata accumulated in recent years have sug- gested strongly that both in-hospital and long-term survival after acute myocardial 
infarction can be increased significantly by mea- 
sures that achieve early and sustained patency of 
the infarct-related coronary artery.14 Thrombolytic 
therapy is one means of effectively restoring ante- 
grade coronary flow in a high proportion of treated 
patients. Thrombolysis alone does little, however, 
to alter the underlying vessel wall disease that 
precipitated the acute ischemic event. As a result, 
infarct vessel reocclusion is relatively common and 
is associated with a high incidence of adverse 
clinical outcomes.’ In an attempt to reduce the 
likelihood of recurrent myocardial ischemia and to 
facilitate left ventricular functional recovery after 
myocardial reperfusion, mechanical revasculariza- 
tion therapies, including coronary balloon angio- 
plasty and coronary artery bypass grafting, have 
been systematically evaluated by many investiga- 
tors as adjuncts to pharmacologic thrombolysis. 
In 1982, Meyer and colleagues’ described the 
use of percutaneous transluminal coronary angio- 
plasty (PTCA) to dilate high-grade residual coro- 
nary stenoses after successful thrombolysis. In this 
small retrospective study, PTCA was attempted in 
21 patients between 20 minutes and 31 hours after 
intracoronary administration of streptokinase. The 
procedure was successful in 17 patients; there were 
no in-hospital reocclusions and the late follow-up 
period was characterized by a low incidence of 
recurrent myocardial ischemia. In contrast, recur- 
rent myocardial infarction occurred during the 
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initial hospitalization in 4 of 18 patients treated 
medically after intracoronary thrombolysis, and 3 
patients died during the follow-up period.’ Early 
surgical revascularization following successful intra- 
coronary thrombolysis for evolving myocardial in- 
farction was also reported to be associated with a 
favorable long-term outcome by Mathey and col- 
leagues.’ These 2 studies focused attention on the 
possibility of a combined pharmacologic and me- 
chanical approach to restoring and maintaining 
antegrade coronary flow as the definitive treatment 
for acute myocardial infarction. In the intervening 
10 years since the publication of these reports, the 
use of thrombolytic therapy has become firmly 
established as the first line of therapy for a substan- 
tial proportion of patients,” but the need for, and 
optimal timing of, adjuvant mechanical revascular- 
ization to prevent late complications in this popula- 
tion remains somewhat controversial. Several post- 
thrombolytic revascularization strategies have been 
examined in multicenter, randomized, controlled 
trials. These include PTCA immediately after suc- 
cessful thrombolysis or for thrombolytic failure, 
late (usually predischarge) PTCA of residual criti- 
cal stenoses in patent infarct-related arteries, and 
selective PTCA, in which mechanical revasculariza- 
tion is reserved for patients with recurrent, sponta- 
neous or stress-induced postinfarction myocardial 
ischemia. 
THROMEOl.YSlS AND IMMEDIATE 
PERcuTANEous mAluSl.uMlNAL CORONARV 
ANaoPlAslY 
The role of balloon dilation of residual coronary 
stenoses in patent arteries immediately after suc- 
cessful thrombolysis has been well studied in ran- 
domized, controlled clinical trials. Three large 
trials compared immediate PTCA with a deferred 
interventional strategy in patients who had re- 
ceived intravenous recombinant tissue plasmino- 
gen activator (rt-PA).“-13 Although the underlying 
hypothesis was the same for each of the studies, 
there were several important differences in study 
design among the trials. In the Thrombolysis and 
Angioplasty in Myocardial Infarction (TAMI) 
trial,” patients presenting within 4 hours of symp- 
tom onset underwent diagnostic coronary angiogra- 
phy 90 minutes after the initiation of the thrombo- 
lytic infusion. Only those patients with patent 
infarct vessels and anatomy deemed suitable for 
PTCA were then randomized to immediate coro- 
nary angioplasty or to repeat cardiac catheteriza- 
tion and PTCA prior to hospital discharge. In the 
Thrombolysis in Myocardial Infarction (TIMI-IIA) 
study, 12*13 randomization to 1 of 3 treatment strate- 
gies was performed prior to coronary angiography. 
Immediate PTCA (including dilation of persis- 
tently occluded arteries), was compared first with 
deferred coronary angiography and PTCA of suit- 
able stenoses, performed 18-48 hours after the 
administration of thrombolytic therapy, and sec- 
ond, with a conservative strategy that consisted of 
predischarge coronary angiography in all patients 
and PTCA only in patients with exercise-induced 
ischemia and appropriate coronary anatomy. In 
the European Cooperative Study Group (ECSG) 
trial,14 eligible patients were randomly allocated 
either to a strategy of immediate coronary angio- 
plasty, including PTCA of persistently occluded 
arteries, or to a strategy in which coronary angiog- 
raphy without PTCA was performed lo-20 days 
after admission. Because of these differences in 
study design, there were important differences 
between the trials in the frequency with which 
mechanical revascularization was actually per- 
formed. Coronary angioplasty was attempted in 
100% of patients randomized to the immediate 
PTCA group in TAMI, compared with 72% in 
TIMI-IIA and 92% in ECSG. Similarly, in the 
deferred intervention groups, PTCA was per- 
formed in 52% of the patients in TAMI, but in 55% 
in TIMI-IIA and 6% in ECSG. 
Despite these differences in trial design, the 
conclusions of the respective study groups were 
remarkably concordant. The principal end point 
for each study was left ventricular ejection fraction, 
determined by contrast ventriculography per- 
formed prior to hospital discharge. Each of the 3 
trials concluded that immediate PTCA did not 
improve the extent of left ventricular global or 
regional functional recovery during the early conva- 
lescent period (Figure 1). Moreover, in each study, 
immediate intervention was associated with an 
increased incidence of procedural complications 
(including the need for emergency coronary artery 
bypass surgery and blood transfusion), no reduc- 
tion in the incidence of reocclusion and reinfarc- 
tion, and a trend toward an increased in-hospital 
mortality (Table I). 
Studies of PTCA immediately after successful 
thrombolysis using agents other than rt-PA have 
also shown no significant advantage of this strategy 
over a deferred PTCA approach. Erbel and col- 
league? randomly assigned 206 patients with acute 
myocardial infarction to immediate angioplasty or 
no PTCA after initial treatment with combined 
intravenous and intracoronary streptokinase and 
mechanical recanalization using a flexible guide 
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TABLE I Clinical Outcomes in the Trials of Intravenous Tissue 
Plasminogen Activator and Immediate Percutaneous 
Transluminal Coronary Angiography: Comparison of Immediate 
and Deferred Interventional Strategies 
TAMI ECSG TIMI-IIA 
(n = 386) (n = 367) (n = 389) 
In-hospital mortality (%) 
Immediate 4 7 8 
Deferred 1 3 5 
Reocclusion (%) 
Immediate 11 12.5 
Deferred 13 11 - 
Emergency CABG (%I 
Immediate 7 3 5 
Deferred 2 0 3 
Blood transfusion (%I 
Immediate 21 10 11 
Deferred 14 4 3 
CABG = coronary artery bypass graft surgery; ECSG = European Cooperative Study 
Broup; TAMI = Thrombolysis and Angioplasty in Myocardial Infarction Trial; TIMI = 
Thmmbolysis in Myocardial Infarction trial. 
wire. Coronary angioplasty was attempted in all 
but 2 of the patients assigned to immediate PTCA, 
including patients with complex coronary anatomy, 
but was considered to have been successful in only 
69% of these attempts. No difference in clinical 
outcome or mortality was apparent after 3 years 
follow-up. Coronary reocclusion or reinfarction 
occurred in 18% of patients undergoing immedi- 
ate PTCA compared with 29% in the conserva- 
tively treated patients (p = nonsignificant) and 
the 3- year survival rates were 80% and 78%, 
respectively. _ 
PolEMnAl EXPIANATIONS FOR THE NEGATIVE 
IMPACT OF IMMEDIATE PERCUTANEOUS 
TRANSUMINAL CORONARY ANQloPLAslY 
From the above studies, it appears that immedi- 
ate PTCA after successful pharmacologic thrombol- 
ysis has no role in the routine management of acute 
myocardial infarction. Several explanations may 
account for the failure of this therapeutic ap- 
proach. Conceivably, the results may be falsely 
negative because of the inclusion of inappropriate 
patients or the selection of insensitive end points 
or, alternatively, immediate PTCA may be truly 
detrimental and may actually promote adverse 
outcomes. 
First, several trial design issues should be consid- 
ered. One potential explanation for the lack of 
benefit of immediate mechanical revascularization 
in these studies may be that global and regional left 
ventricular function are insensitive endpoints that 
poorly reflect the potential impact of a therapy on 
long-term postinfarction surviva1.3*‘6 Indeed, sev- 
eral studies have shown clearly that early myocar- 
dial reperfusion therapy may increase long-term 
survival in the absence of a demonstrable effect on 
left ventricular functional recovery.1,17,‘s In part, 
this lack of sensitivity may arise because patients 
selected for inclusion in the trials had well pre- 
served global left ventricular function at presenta- 
tion; the mean predischarge left ventricular ejec- 
tion fraction for the 953 patients in the 3 rt-PA and 
immediate PTCA trials was 51%. A second possibil- 
ity is that the duration of the initial follow-up 
period may have been inadequate to demonstrate 
improvement in left ventricular functional recovery 
and a reduction in late adverse events. However, 
careful assessment of late events and out-of- 
hospital survival of patients enrolled in the TIM1 
study13 showed that at 6 weeks, no difference was 
apparent between the groups in resting left ventric- 
ular ejection fraction, peak exercise ejection frac- 
tion or infarct zone segmental ejection fraction 
(Table II). Similarly, clinical follow-up 12 months 
postinfarction showed no difference in the cumula- 
tive incidence of recurrent myocardial infarction, 
the need for coronary artery bypass graft surgery or 
death, despite a considerable difference in the 
frequency with which coronary angioplasty was 
performed in the 3 groups (Table II). Finally, the 
inclusion of patients with noncritical residual steno- 
ses may have obscured recognition of a positive 
impact of PTCA in patients with critical stenoses, 
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the group at greatest risk of reocclusion and in 
whom flow restriction is most likely to compromise 
left ventricular functional recovery.‘9-22 This possi- 
bility was explored by Belenkie and co11eagues23 in
a recent randomized study of immediate PTCA 
versus PTCA performed 18-48 hours after intrave- 
nous thrombolysis. In the study, the angiographic 
and left ventricular functional outcomes were strat- 
ified according to the adequacy of thrombolytic 
reperfusion and correlated with the incidence of 
reocclusion.23 Ineffective reperfusion was defined 
as a residual lumen diameter stenosis >90% or 
delayed distal filling at the time of the initial 
diagnostic coronary angiogram. Reocclusion dur- 
ing the 18-48 hours before the scheduled angio- 
graphic procedure in patients assigned to the 
delayed PTCA strategy occurred in 37% of the 
patients with ineffective reperfusion compared with 
5% of those with effective reperfusion (p = 0.02). 
Improvement in regional, but not global, left ven- 
tricular function was also greater in patients with 
initially ineffective reperfusion. However, neither 
the frequency of reocclusion nor the left ventricu- 
lar functional recovery was influenced by whether 
PTCA was performed immediately or at 18-48 
hours.23 
More likely than any of the methodologic consid- 
erations mentioned is the possibility that balloon 
dilation is truly detrimental and actually incites 
further thrombus formation and reocclusion in 
patients with freshly disrupted atheromatous 
plaques, even in the presence of systemic fibrino- 
genolysis. The presence of an intraluminal throm- 
bus is known to be a risk factor for abrupt occlusion 
during elective coronary angioplasty,24-*6 and for 
procedural failure in the setting of acute myocar- 
dial infarction.27 Nonrandomized, retrospective 
studies have also suggested that elective balloon 
angioplasty performed within 1 week of symptom 
onset in patients with unstable coronary syndromes 
is associated with a lower success rate and a higher 
incidence of major procedural complications than 
a deferred PTCA strategy.28 Several studies have 
described the histopathologic appearance of coro- 
nary arteries after sequential thrombolysis and 
balloon dilation in patients dying during the early 
postinfarction period.29,30 In one study,30 prominent 
intramural hemorrhage was noted at the site of 
balloon dilation, and in 1 patient, medial hemor- 
rhage resulted in subtotal occlusion of the dilated 
vessel. 
Whether immediate PTCA would become a 
valuable strategy if reocclusion could be prevented 
by more potent antithrombin and antiplatelet 
TABLE II Delayed, Elective Intervention and a Conservative 
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LVEF = left ventricular ejection fraction; SWIFT = Should We Intervene Following 
Thrombolysis? trial; TM = Thmmbolysis In Myocardial Infarction trial; t-PA = tissue 
plasminogen activator. 
*Total hemorrhagic events. 
agents, or by other interventional procedures such 
as directional coronary atherectomy or laser bal- 
loon angioplasty, is at present unclear. This possi- 
bility was suggested by a recent retrospective anal- 
ysis of the results of the ECSG trial.31 The study 
examined the effects of immediate PTCA on left 
ventricular functional recovery in the subgroup of 
patients with successful reperfusion and sustained 
patency of the infarct artery. In these patients, 
global left ventricular function was somewhat bet- 
ter in the immediate PTCA group (left ventricular 
ejection fraction 50.8% vs 49.0%) due principally 
to a less extensive segment of regional infarct zone 
dysfunction.31 At the present time, however, the 
potential hazards of these procedures appear to 
outweigh this relatively small benefit, and there do 
not appear to be any data to suggest that immedi- 
ate PTCA should be performed routinely following 
successful thrombolysis, no matter how severe the 
residual coronary stenosis. 
RESCUE CORONAKYANQlOPlASTY 
In contrast to the apparent consensus of opinion 
on the role of immediate PTCA of successfully 
recanalized infarct vessels, opinions on the impor- 
tance of emergency balloon dilation of persistently 
occluded coronary arteries remain divergent, prima- 
rily because of a lack of relevant randomized data. 
Data from several observational studies do suggest, 
however, that rescue coronary angioplasty may be 
of value for thrombolytic failure in selected pa- 
tients. The combined experience of rescue coro- 
nary angioplasty in the first 5 TAM1 studies was 
recently reported.32 In this retrospective analysis, 
the in-hospital and long-term outcomes of 607 
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patients with successful thrombolysis were com- 
pared with the outcomes of 169 patients with 
successful rescue PTCA following failed intrave- 
nous thrombolysis. Although the overall in-hospi- 
tal and long-term mortalities were similar in the 2 
groups (4.6% vs 5.9% and 2% vs 3%, respectively), 
the incidence of reocclusion of the infarct-related 
artery was considerably higher following rescue 
angioplasty than following successful pharmaco- 
logic thrombolysis (21% vs ll%, p <O.OOl) (Fig- 
ure 2). This increased reocclusion rate was associ- 
ated with significantly less improvement in both 
global and regional left ventricular functional recov- 
ery. Importantly, the incidence of reocclusion ap- 
peared to be markedly influenced by the thrombo- 
lytic regimen. Reocclusion after successful rescue 
PTCA occurred in 29% of patients treated with 
rt-PA alone, compared with 12% of patients treated 
with intravenous urokinase and 4% of patients 
treated with the combination of rt-PA and uroki- 
nase (p <0.019). These findings are consistent 
with previous observations of a very high reocclu- 
sion rate following PTCA for unsuccessful rt-PA 
therap? and lower, but nonetheless significant, 
reocclusion rates following the use of agents with 
more profound systemic fibrinolytic potentia1.3G3g 
Several explanations have been offered for the high 
reocclusion rate after successful rescue PTCA.32,40*41 
Postmortem studies have suggested that atheroma- 
tous plaque at the site of acute occlusion in 
patients in whom pharmacologic thrombolysis has 
failed to restore luminal patency is characterized 
by more extensive fissuring and disruption, with a 
greater component of intramural, platelet-rich 
thrombus that is relatively resistant to systemic 
fibrinolysis. Balloon dilation may simply extend the 
intimal fissure and aggravate an already highly 
thrombogenic focus. 
Data from the TAM1 study group experience 
also suggest that failure of rescue angioplasty to 
restore infarct vessel patency may be associated 
with a considerably increased early postinfarction 
mortality.32 Although the overall mortality of pa- 
tients undergoing rescue PTCA was 9.9%, the 
in-hospital mortality following successful rescue 
PTCA was 5.9% compared with 39.1% in patients 
in whom the procedure failed to restore antegrade 
flow (Figure 3). Although this may, in part, reflect 
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pharmacologic thrombolysis may be inherently 
sicker and more hemodynamically compromised), 
it may also indicate that rescue angioplasty can 
precipitate hemodynamic and electrical instability. 
This latter explanation may be particularly true for 
rescue angioplasty of persistently occluded right 
coronary arteries, a procedure that appears to be 
associated with an increased risk of heart block and 
life-threatening ventricular arrhythmias?’ 
In addition to a retrospective analysis of the 
value of rescue angioplasty,39 the TAM1 study 
group has recently reported the results of a study 
that prospectively compared an aggressive interven- 
tional strategy with a more conservative post- 
thrombolytic strategy.” In TAMI-V, 575 patients 
were randomly assigned to undergo immediate 
coronary angiography with rescue angioplasty for 
failed thrombolysis, or predischarge cardiac cathe- 
terization after the administration of intravenous 
rt-PA, urokinase, or the combination of rt-PA and 
urokinase. The aggressive strategy was associated 
with a somewhat better predischarge regional in- 
farct zone wall motion (-2.16 vs -2.49 standard 
deviations/chord, p = 0.004) and greater freedom 
p = 0.004) (F’gu 1 res 4 and 5). In-hospital mortality 
was, however, slightly higher in the aggressively 
treated group (6% vs 4%), but this difference did 
not reach statistical significance. 
The findings of these studies suggest that the 
role of rescue coronary angioplasty for failed phar- 
macologic therapy has not yet been defined ade- 
quately. Ongoing randomized trials will, it is hoped,, 
further define the relative risks and benefits of this 
approach and may identify subgroups of patients in 
whom meaningful clinical benefits outweigh the 
potential hazards. Attention must also be given in 
future studies to the appropriate timing of mechan- 
ical revascularization in this setting. Convention- 
ally, the angiographic success of pharmacologic 
thrombolysis has been recorded 90 minutes after 
initiation of the thrombolytic infusion. Thromboly- 
sis continues beyond this point, however, and the 
patency rate may increase considerably between 90 
minutes and 2&36 hours.43 It is conceivable, there- 
fore, that in some patients, PTCA of persistently 
occluded vessels could be deferred (to increase the 
likelihood of pharmacologic thrombolysis) without 
adversely affecting the extent of myocardial salvage 
from adverse clinical outcomes (67% vs 55%, or the likelihood of subsequent survival. 
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CONSERVATIVE POST-THROMBOLYTIC 
STRATEGY 
The failure of immediate PTCA to improve the 
short- and long-term clinical outcome of patients 
treated with intravenous thrombolysis in 3 well- 
controlled studies raised questions about the need 
for mechanical intervention, and even routine 
diagnostic coronary angiography, at any time in the 
postinfarction period. A conservative, noninvasive 
strategy was, therefore, evaluated in 2 large, ran- 
domized trials.aV45 After showing no advantage of 
immediate PTCA over deferred intervention, the 
TIM1 study group compared a deferred PTCA 
strategy to a noninvasive strategy in a much larger 
population of patients.44 Following the administra- 
tion of intravenous rt-PA, 3,262 patients were 
randomly allocated to undergo either coronary 
angiography and balloon dilation of suitable infarct 
vessel stenoses 18-48 hours after admission, or to a 
conservative strategy. Patients in the latter group 
underwent diagnostic coronary angiography and 
mechanical revascularization only if myocardial 
ischemia recurred prior to hospital discharge, or if 
a predischarge functional study showed exercise- 
induced ischemia. Of the 1,636 patients assigned to 
the invasive strategy, 928 (56.7%) underwent at- 
tempted PTCA; 216 (13.2%) of the conservatively 
treated patients required PTCA within 14 days of 
admission for recurrent or provocable ischemia. 
The principal end points of the study were the 
incidence of reinfarction or death within 6 weeks of 
presentation. Secondary end points included rest 
and exercise left ventricular ejection fraction and 
exercise-induced myocardial ischemia. The study 
concluded that the conservative, clinically driven 
interventional strategy was associated with a clini- 
cal outcome that was at least as favorable as the 
more aggressive and invasive interventional strat- 
egy. The 2 groups were well matched with respect 
to age and sex distribution, time to treatment, and 
clinical condition at presentation. The early postin- 
farction survival was excellent in both groups, with 
a cumulative 6-week mortality of 5.2% in the 
invasive group compared with 4.7% in the conser- 
vatively treated group. Reinfarction occurred within 
the first 6 weeks in 5.9% and 5.4%, respectively 
(Figure 5). Similarly, no difference was apparent 
between the groups in resting left ventricular 
ejection fraction at hospital discharge (50.5% vs 
49.9%, p = 0.30), or at 6 weeks (50.0% vs 50.4%, 
p=O.51) (Table II). There was, however, a greater 
stress-induced increase in ejection fraction in the 
invasive strategy group (3.3% vs 2.3%, p = 0.02) 
and a higher incidence of exercise-induced myocar- 
dial ischemia in the conservatively treated patients 
(17.7% vs 12.8%, p < 0.001). 
The major conclusion of this study, that most 
patients can be successfully managed conserva- 
tively following thrombolysis, is supported by the 
findings of a European multicenter trial of delayed 
elective mechanical revascularization versus conser- 
vative therapy after intravenous anisoylated plas- 
minogen activator complex therapy.45 Patients who 
were pain free and hemodynamically stable during 
the first 24 hours of hospital admission were 
randomly assigned in the SWIFT (Should We 
Intervene Following Thrombolysis?) trial to one of 
2 post-thrombolytic strategies. Patients assigned to 
the invasive strategy underwent diagnostic coro- 
nary angiography and, if appropriate, mechanical 
revascularization within 48 hours of randomiza- 
tion. Balloon dilation of persistently occluded ves- 
sels was not encouraged. As in the TIMI-IIB study, 
coronary angiography with mechanical revascular- 
ization was performed on patients assigned to the 
conventional care group only if they developed 
recurrent postinfarction angina or had stress- 
induced ischemia. Of the 397 patients assigned to 
early intervention, 377 (95%) underwent coronary 
angiography within 7 days of admission and 228 
(57%) were revascularized (169 by balloon dilation 
and 59 by coronary artery bypass graft surgery). In 
contrast, angiography was performed for clinical 
indications in 54 (13%) of 403 patients treated 
conservatively. Of these, only 19 patients (4.7%) 
were revascularized during the initial hospital ad- 
mission, and an additional 40 patients (10%) under- 
went revascularization procedures during the 12- 
month follow-up period. Despite the considerably 
greater frequency of intervention in the invasive 
group, no difference in infarct-free survival was 
apparent between the two groups. The cumulative 
l-year mortality was 5.8% in the intervention 
group compared with 5.0% in the conservative care 
group (p = 0.6) and the incidences of reinfarction 
were 15.1% and 12.9%, respectively (p = 0.4) (Fig- 
ure 5). Similarly, no differences were apparent in 
left ventricular functional recovery or symptom 
status at 12 months (Table II). 
Although these data are very compelling, sev- 
eral factors may limit the interpretation of the 
findings of these 2 studies. First, in both studies, 
PTCA was performed 18-48 hours after intrave- 
nous thrombolysis in the invasive groups, a time 
that, although “deferred,” is still early in the 
convalescent period. Although not formally tested 
in any of the randomized trials, it is possible that 
further deferral of the interventional procedure 
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until at least l-2 weeks postinfarction might im- 
prove procedural outcome by allowing an adequate 
period for plaque stabilization and thrombus reso- 
lution. Angiographic studies have suggested, for 
example, that the morphology of the lesion in the 
infarct-related artery improves progressively over 
the 7-10 days after thrombolytic therapy, with 
resolution of intraluminal filling defects, a reduc- 
tion in contour irregularity and a decrease in 
indices of lesion ulceration.46 Thus, a truly deferred 
interventional strategy has not been tested against 
a noninvasive strategy. Secondly, although 67% of 
patients enrolled in the TIMI-IIB study were 
classified as “not-low-risk,” the in-hospital and 
long-term mortality of patients treated conserva- 
tively in this study and in the SWIFT trial were low, 
suggesting that the patients enrolled may, in fact, 
have had an excellent prognosis, regardless of the 
interventional strategy. Thus, the ability of these 
studies to detect an important difference in out- 
comes may have been limited, and extrapolation of 
the results to higher risk patient subgroups, includ- 
ing the elderly and patients presenting more than 
3-4 hours after symptom onset, should therefore 
be undertaken with some caution. 
MANAGEMENT OF RECURRENT MYOCARDW. 
ISCHEMIA 
If a conservative post-thrombolytic strategy is 
adopted, what then is the optimal management of 
recurrent, myocardial ischemia and hemodynamic 
compromise during the early convalescent period? 
The frequency with which urgent cardiac catheter- 
ization was performed for these complications 
during the initial hospitalization of conservatively 
treated patients has ranged from 12% in the 
TIMI-IIA study” to 26% in the TAMI-V study?’ 
The rationale for aggressive intervention in this 
setting is that angiographic evaluation permits 
appropriate triage to urgent mechanical revascular- 
ization or to continued medical therapy. In nonran- 
domized studies, urgent coronary angioplasty has 
been shown to improve 30-day survival for patients 
with cardiogenic shock4* and to treat acute isch- 
emit mitral valve regurgitation successfu1ly.49 Staged 
balloon angioplasty has also been advocated for 
patients with multivessel coronary artery disease:’ 
a group known to be at increased risk of postinfarc- 
tion mortality?l Similarly, emergency coronary ar- 
tery bypass surgery, performed for unsuccessful 
sequential intravenous rt-PA therapy and coronary 
angioplasty or for severe multivessel disease, has 
been shown to be a safe and effective therapy that, 
in one study, was associated with a substantial 
degree of improvement in both global and regional 
left ventricular function5’ 
This aggressive interventional approach for re- 
current myocardial ischemia or hemodynamic insta- 
bility was recently evaluated by the TAMI-V study 
group>’ Of 288 patients initially allocated to a 
conservative treatment strategy, 54 (19%) under- 
went urgent cardiac catheterization within 24 hours 
and a further 21 patients (7%) required urgent 
intervention during the second to fourth hospital 
days. Coronary angiography showed that the infarct- 
related artery was occluded (TIMI flow grade 0 or 
1) in 39%, but was patent in the remainder. 
Emergency coronary angioplasty was performed in 
49% of the patients and 3% underwent emergency 
coronary artery bypass surgery. Despite this inter- 
vention, the need for urgent cardiac catheteriza- 
tion was associated with an increased in-hospital 
mortality (7% vs 3%, p = 0.36), and poorer predis- 
charge left ventricular function (left ventricular 
ejection fraction 50 * 11% vs 54 & ll%, p=O.12). 
Multivariate analysis of 16 clinically available pa- 
rameters identified only patient age and anterior 
wall myocardial infarction as independent predic- 
tors of the need for urgent intervention. The 
implications of this study are that recurrent isch- 
emia and reinfarction, which are relatively com- 
mon with currently available thrombolytic and 
anticoagulant regimens, are predicted poorly by 
clinical parameters. Further, these complications 
are associated with a significant morbidity and 
mortality despite aggressive interventional ther- 
apy. In the absence of a control group, it is unclear 
whether urgent intervention is the optimal treat- 
ment in this setting; it remains possible that some 
of these patients might respond better to repeated 
administration of intravenous thrombolytic ther- 
apy,s3 but this approach has not yet been ade- 
quately evaluated. 
ROUTINE PRED&CHMGE DlAoNosnC 
coRoHARYAHGloGRAPHY 
The final post-thrombolytic strategy that should 
be considered is routine predischarge coronary 
angiography without routine mechanical revascular- 
ization.54 Using this approach, delineation of the 
coronary anatomy is performed primarily for prog- 
nostic purposes. The value of this approach has not 
been formally tested, but a nonrandomized compar- 
ison of selective and routine coronary angiography 
was performed by the TIM1 study group using data 
acquired in the TIMI-IIA and -1IB studies.SS The 
clinical outcomes of 197 patients assigned in the 
TIMI-IIA study to conservative management and 
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routine predischarge coronary angiography was 
compared with that of 1,461 patients assigned to 
selective cardiac catheterization (for recurrent or 
provocable ischemia) in the TIMI-IIB study. In the 
former group, coronary angiography was actually 
performed on 94% of the eligible patients com- 
pared with 35% of the patients in the selective 
catheterization group; 59.4% of the latter group 
had undergone invasive evaluation by the end of 
the l-year follow-up period. The incidence of 
predischarge mechanical revascularization by coro- 
nary angioplasty or bypass graft surgery was similar 
in the 2 groups. At 1 year, the incidence of death, 
and nonfatal reinfarction were similar in the 2 
groups (Figure 5), but the number of hospital 
readmissions was greater in the selective coronary 
angiography group (37.9% vs 27.6%, p = 0.007). It 
could be concluded from this study that a reduction 
in the number of postinfarction angiographic proce- 
dures by 40% would substantially reduce health 
care costs and the risks to the patient of an 
unnecessary procedure. However, the added costs 
of routine angiography may well be offset by the 
30% reduction in the need for hospital readmission 
and a reduction in the need for repeat (and 
perhaps even predischarge) exercise stress testing. 
Further, knowledge of the coronary anatomy may 
have a positive impact on the timing of hospital 
discharge,56T57 the psychologic health, and the em- 
ployability of patients with a good prognosis, such 
as those with minimal coronary disease58 or disease 
confined to a side branch coronary artery. Finally, 
knowledge of the coronary anatomy may have an 
important influence on the selection of medical 
therapy for patients with uncomplicated infarcts. 
Recent data have suggested, for example, that 
long-term p blockade may reduce postinfarction 
mortality in patients with persistently occluded 
infarct-related arteries.59 
CURREM- RECDMMENDATIDNS 
From the data given, several broad recommen- 
dations can be made for the use of adjuvant 
mechanical revascularization following intrave- 
nous thrombolysis. First, the majority of patients 
can be initially managed without urgent coronary 
angiography and PTCA. Patients with an uncompli- 
cated course should undergo a submaximal stress 
test prior to hospital discharge and, in many cases, 
can be managed medically if the functional study 
shows no evidence of inducible myocardial isch- 
emia. Our own bias is, however, that predischarge, 
diagnostic coronary angiography is a low risk, 
relatively inexpensive investigation that should be 
offered to virtually all patients. Certainly, patients 
with provocable myocardial ischemia should un- 
dergo coronary angiography, preferably before hos- 
pital discharge, and, depending on the coronary 
anatomy, should then undergo elective mechanical 
revascularization of diseased arterial segments. In 
centers with active cardiac catheterization labora- 
tories, early coronary angiography (days 4 to 6) 
should be considered with a view to early patient 
discharge and return to work, particularly for 
young, otherwise healthy patients without evidence 
of extensive myocardial infarction. In patients with 
evidence of a large, evolving myocardial infarction, 
persisting ischemic chest pain or hemodynamic 
instability at the time of admission, urgent coro- 
nary angiography remains a valuable diagnostic 
tool that permits triage to rescue PTCA for persis- 
tently occluded infarct vessels, urgent coronary 
artery bypass grafting for severe left main or triple 
vessel coronary disease or to medical therapy (and 
perhaps intra-aortic balloon pump support) if the 
infarct vessel is patent. This schema will undoubt- 
edly require modification as data from ongoing 
clinical investigations become available and as 
more reliable noninvasive means are identified for 
determining peri- and postinfarction mortality risk 
for individual patients. 
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